Prot #TPU-TAS-102-109: A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination with CPT-11 and Bevacizumab in Patients with Advanced Gastrointestinal Tumors

Project: Research project

StatusFinished
Effective start/end date10/16/1510/16/18

Funding

  • Medpace, Inc. (Prot #TPU-TAS-102-109)
  • Taiho Oncology, Inc. (Prot #TPU-TAS-102-109)